This round is no longer accepting investments, but hundreds just like it are live now.

Log In


Must love horses! Save lives while investing in innovative tech

Prisma is developing and intends to bring to market a novel system that is capable of providing both digital radiographic and CT imaging of the entire anatomy of a conscious, weight-bearing horse. This development represents an opportunity to improve upon existing imaging employed in the equine industry and will displace traditional CT imaging. These improvements represent the ability to provide better diagnostics, performance, care, and promote the health and welfare of horses compared to current imaging options.

This Reg CF offering is made available through StartEngine Capital, LLC. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment.

$36,995.05 Raised

Reasons to Invest

  • Horses are needlessly suffering and experiencing career-ending or even catastrophic, fatal injuries. The life-saving diagnostics that would keep them safe, healthy, and promote a better quality of life, CT imaging, is grossly underutilized because of its cost, difficulty to implement, and is a potential risk to the horse’s health and safety. Prisma’s “game-changing” technology offers a solution that addresses these shortcomings.

  • Prisma’s technical lead and co-development partner is Triple Ring Technologies, one of the industry leaders in developing advanced imaging technology that has the skill sets to execute the system’s final push to commercial readiness. Triple Ring is also an investor in Prisma. 

  • Prisma has secured a venture capital investor, Kirenaga Partners. Having investments and being vetted by Kirenaga and Triple Ring, is a great vote of confidence in the viability of achieving commercial success.


A healthy-sized industry - Why we should care?

A recent study conducted by the American Horse Council Foundation (source) revealed that the economic activity involved in caring for the nation's 7.2 million horses directly contributes over $122 billion to America's Gross Domestic Product and 1.7 million jobs. The US horse population of 7.2 million is a fraction of the worldwide equine population which totals a staggering 50 million horses. 

However, to be successful, horses need to be healthy. 


According to our research, horses are prey animals, which means that instinctively they will hide any signs of injury or distress to avoid being the next meal for a predator that looks for the weak to make an easy kill. Unlike Mr. Ed, our 4-legged friends can’t tell us when they’re hurt, and most catastrophic, fatal occurrences are caused by latent injuries or defects in the skeletal system that go undetected. So, an efficient, effective way to discover these problems will reduce these tragedies and help save lives.


Current CT Radiology has too many limitations

Current imaging technology has several limitations and is not well-suited for horses. It requires the patient to be anesthetized which is dangerous and potentially life-threatening for the horse and unsafe for medical personnel ( source). It also necessitates a team to awkwardly position an unconscious twelve-hundred-pound patient into a CT donut. Lastly, it can’t image the high-mass parts of the equine anatomy which often leads to an incomplete or faulty diagnosis.

Issues with this current imaging technology:

  • Requires horses to be anesthetized, which can be potentially dangerous for the patient
  • Significant added cost, difficult to implement, and requires multiple personnel 
  • Cannot show certain high-mass body parts (abdomen, hips, axial skeleton)


Technology that prioritizes equine health and safety

* Prisma Imaging products shown in the above video are in the prototype phase. Product is not currently available on the market.

Prisma’s technology will be easy to implement and safe for both the horse and handler. The horse is walked into position and requires only mild sedation; Robotics provides unlimited access to virtually every anatomical region of a standing, conscious horse including the axial skeleton, hips, pelvis, and abdomen. Prisma’s system utilizes two types of radiographic imaging technologies which reveal the high-mass areas of the equine anatomy and generates high-resolution images that current imaging technology can’t do. The horse is safely in and out fast.


We believe that none of the attempts to build equine CT systems offer a comprehensive solution to image the entire anatomy. Or worse, they make anesthesia necessary which is potentially dangerous and life-threatening for the patient. According to insights from our research, systems 1 and 2 are essentially repurposed CT equipment from the human market and are considerably more expensive compared to the Prisma system. System 4 had the right idea in using robots, but they never developed a working system and has been out of business since 2016. System 5, which also uses robots, has yet to produce diagnostic quality CT images and can’t image the high-mass parts of the horse, which is a shortcoming of System 3 as well. We believe Prisma offers superior capabilities and other innovations, which you’ll see later, between current radiographic imaging technology and these ventures. 


According to our research, Prisma is one of the only standing CT systems that employs advanced design to ensure that the horse and the handler are safe during the imaging process.

*The above is a rendering of a future product. Images are computer generated demo versions. Product is still currently under development not yet available on the market.

*The above is a rendering of a future product. Images are computer generated demo versions. Product is still currently under development not yet available on the market.


Multi-Billion Dollar Market for Prisma’s Technology

Source: Jockey Club

The obvious beneficiaries of Prisma’s imaging technology will be horses that are in the competitive sectors. According to our research, in looking at these categories in the US, racing and showing, a consensus among trainers, horse owners and vets revealed that a horse that is active in the racing sector should be proactively imaged a minimum of 4 times a year. The company believes that, in the US, approximately 200,000 out of the 1.2 million horses in the racing category are actively involved in training and competition. The determination of the appropriate number of scans was based on a horse’s race schedule, training regimen and medical history. Also taken into consideration was the advanced, safe and efficient functionality of Prisma’s system, especially since the horse does not need to be anesthetized, and our ability to image the axial skeleton. At $1,000/study, this equates to a TAM of $800 million for the racing category. 

Based on discussions we've had with trainers, owners and vets, the company believes that for the showing category active participants, which in the US is approximately 600,000 out of the 1.2 million population, the consensus was that they should be proactively imaged a minimum of once a year. The determination for the frequency was arrived at with a similar methodology as racing. At $1,000/study, this equates to a TAM of $600 million for the showing category. Looking at the remaining 3.1 million recreational horses in the US, the worldwide equine population of 50 million and based on a consensus from medical professionals, we may conclude that there is a multi-billion- dollar market opportunity for Prisma’s imaging technology.


*The above testimonials are personal opinions and are not a guarantee of future financial performance or success

Since its inception, Prisma has been in regular contact with a number of research universities, large equine veterinary practices and major equine industry organizations, all of which are very supportive and enthusiastic about the technology we are developing and the benefits that it will provide to the equine industry. We have strong levels of interest from these parties and they are excited to see the commercialization of our technology

A functional working prototype system exists and the first “field-ready” system is being installed at an equine veterinary practice in July. We hope to begin commercial sales in early 2023.   

As we move toward commercialization, Prisma’s business model will be based on a three-segment sale strategy for the equine market: 

  • Academic research institutions
  • Large equine clinics
  • Company developed and operated mobile imaging systems


Technical advancements from initially operating within the equine industry will create opportunities to develop other potential applications. For example, other large animals in zoos and nature preserves, the cattle and food animal industry, and even in the human market to address the imaging challenges for the growing bariatric population.


Other potential opportunities will come from newly available data about the equine patient’s axial skeleton made possible by Prisma’s technology that will be accumulated from the system’s utilization. This valuable data will be correlated to the horses’ performance during their competitive career. Eventually, the aggregated results could be used as a predictor of a horses’ performance potential and other important characteristics that will benefit the industry.


Improving quality of life for horses everywhere

Prisma Imaging offers investors the opportunity to be part of one of the next disruptors in promoting better care and safer, more humane existence for our beloved horses.

Additionally, Kirenaga Partners has institutionally vetted us and has been taking the lead investment in Prisma’s current seed round, which is a great vote of confidence in the technology that Prisma has developed. This is further amplified by also having the financial support of Triple Ring Technologies, Prisma’s technical lead and co-development partner, as they are experienced in the imaging industry.

*The above is a rendering of a future product. Images are computer generated demo versions. Product is still currently under development not yet available on the market.

In the future, we envision our ground-breaking, highly beneficial diagnostic technology supporting the sustainable, humane treatment of animals in all categories, including our beloved pets, animals that live in captivity (in zoos and nature habitats), and in our food chain. 

Prisma is on the precipice of becoming the next disruptor in equine diagnostics, paving the way for a healthier, safer, more humane quality of life for our beloved horses.  

Prisma Imaging 17b Disclosure


13900 Tech City Circle, Suite #200
Alachua, FL 32615

Prisma is developing and intends to bring to market a novel system that is capable of providing both digital radiographic and CT imaging of the entire anatomy of a conscious, weight-bearing horse. This development represents an opportunity to improve upon existing imaging employed in the equine industry and will displace traditional CT imaging. These improvements represent the ability to provide better diagnostics, performance, care, and promote the health and welfare of horses compared to current imaging options.


Michael Silver
Michael Silver
Founder & Chief Executive Officer & Board of Directors Member

Michael has over 30 years of entrepreneurial and institutional experience. From 1992 until 2001, he worked for Ronald Perelman’s holding company, MacAndrews and Forbes, Inc., where he worked in a variety of capacities at the M&F companies. In 2002, he started a company, in the housewares industry that he built and successfully divested in 2012. After selling his company, Michael started Prisma Imaging in 2016. His motivation to start Prisma was to develop a solution that addressed the deficiencies that exist in equine imaging, his desire to create new beneficial technology, and his attraction to the contagious passion that exists within the equestrian community. Michael is committed to Prisma for the long-term, beyond the equine market and into the next phase of potential expanded industries that will become viable as Prisma’s technology advances.  

In addition to recognizing the merits of developing a ground-breaking, highly beneficial diagnostic technology, Michael is equally committed to supporting the humane treatment of animals in all categories, including our beloved pets, animals that live in captivity (in zoos and nature habitats), and in our food chain. 

Michael received his BA from Vanderbilt University and his MBA from Fordham. 

Brian Tisher
Brian Tisher
Co-Founder & Chief Financial Officer

Brian serves as chief financial officer for Prisma and is a seasoned healthcare administrator bringing 25 years of experience within the healthcare sector including leadership roles in financial management, strategic development, and healthcare operations. His experience includes 20 years working as a healthcare administrator in the Atlanta healthcare market including positions with Emory University System of Healthcare, Saint Joseph's Health System, and Hospital Corporation of America (HCA) where he worked to develop some of the most successful physician-integration strategies in the Atlanta market.

Brian provides a broad range of experience in health services delivery having worked within both hospital and physician management settings, including for profit/not-for-profit, and academic medical center environments. Brian serves as adjunct program faculty for the University of Florida’s Master of Health Administration program teaching healthcare financial management.

Brian received an MBA/MHS Degree from the Warrington College of Business at the University of Florida, where he also earned a certificate degree in Entrepreneurship. He holds a BS in Communications, also from the University of Florida.

David Scalzo

David Scalzo

Board of Directors Member

David Scalzo is the Founder and Managing Partner for Kirenaga Partners.

David co-founded the fintech company AdvisorEngine, served as its first CFO and sat on the Board of Directors until its sale to FranklinTempleton. In addition, he has extensive experience initiating, growing and managing businesses through various roles at Credit Suisse, Citadel, Bear Stearns, and Precision Plating Company.

David serves on the Board for the Northwestern University Wildcat Athletic Venture Enterprise (NU/WAVE) investment fund, as well as numerous former and current portfolio companies.

David graduated with a BS in Mechanical Engineering from Northwestern University, a Masters in Manufacturing Engineering from the Illinois Institute of Technology, a Masters in Engineering Management from Northwestern University, and a Masters in Business Administration from the Kellogg School of Management at Northwestern University.

Dr.  Joseph Heanue

Dr. Joseph Heanue

Board of Directors member

Dr. Joe Heanue has significant leadership experience in device and instrumentation research & development within interdisciplinary environments. He previously served as Vice President of Engineering at NexRay and at Signature Bioscience. At NexRay, Joe led the development of a low-dose x-ray imaging system for interventional cardiology. At Signature, he headed a group that delivered prototype RF and microwave spectroscopy instruments to a major instrument partner; the first of these instruments was launched in 2005 by MDS Sciex.  

Joe’s extensive research and development experience includes the analysis and design of complex systems, x-ray and gamma-ray detector development, low-noise analog electronics, data-acquisition systems, signal and image processing, high-speed data-processing architectures, and thin-films failure analysis.  

Joe holds patents for detector and image processing, spectroscopy, and a patent for medical system imaging architecture that is licensed to a major medical equipment manufacturer. He received a BS in Physics from the Massachusetts Institute of Technology and earned his Ph.D. in Electrical Engineering and Computer Science from the University of California at Berkeley. Joe was a postdoctoral researcher at Xerox PARC, and he has completed the Stanford University Executive Program for Growing Companies. 

Dr. Sheetal Patel

Dr. Sheetal Patel

Board of Directors member

Dr. Sheetal Patel began her career as a board certified Radiologist, earning her medical degree from University of Miami School of Medicine and going on to complete a residency in Radiology with University of South Florida in Tampa. She furthered her training with a fellowship in Musculoskeletal Radiology, a subspecialty which focuses on sports and orthopedic imaging (including bone and soft tissue tumors). After completing her residency and fellowship she worked with one of the top Radiology groups in Tampa, FL for 9 years.

In 2014, while still practicing radiology, Dr. Patel completed her MBA at University of South Florida, finishing at the top of her class. Soon after earning her MBA she became more actively involved in various business endeavors. Gradually over the course of the next 2-3 years, she transitioned fully into a business role and away from practicing medicine, leading to her current role as COO of the Patel Family Office.

As COO of the Patel Family Office she coordinates operations and investment management across all portfolios. In addition, she actively manages the family’s real estate portfolio consisting of just under $1B in assets across the hospitality, commercial real estate, and development sectors.

Additionally, Dr. Patel is involved with various non-profit and charitable endeavors in the medical and education arenas both within and outside of the Patel Family Foundation which has projects both in the US and abroad. Locally, she also supports the Tampa Bay area as Vice President and board member of The Charity Polo Classic, an organization whose mission is “making a difference by collaborating with local charities to build a better Tampa Bay”. 

Dr. Tobias Funk

Dr. Tobias Funk

Technical Advisor

Dr.Tobias Funk has years of experience in the development of instrumentation for science and medicine. Tobias is an experimental solid-state physicist by training and has focused on utilization of ionizing radiation throughout his career. He developed synchrotron instrumentation for spectroscopy on proteins and ultra-low temperature equipment for nuclear solid-state physics. He has authored over 20 peer-reviewed publications and has over 10 granted and pending patents. 

Hailey Gryka

Hailey Gryka

Technical Advisor

Hailey’s area of expertise lies at the interface of bioinstrumentation and data science. Her experience is in a broad range of bioinstrumentation including magnetic resonance imaging development, point of care device design and testing, neutron generator and linear accelerators for use in healthcare, and development of data processing and machine learning technologies. She has been involved in various stages of the product development pipeline, from design verification to manufacturing quality control. 

Christopher Ellenor, PhD

Christopher Ellenor, PhD

Technical Advisor

Dr.Christopher Ellenor has experience building experimental systems comprising diverse technical elements. He has great experience on working on laser cooling, imaging and optical design, magnetic trapping of atoms, coil design and ultra-high vacuum (UHV) systems, MRI systems, with a focus on RF safety, as well as embedded and wireless electronics for sensing of patient motion and RF current. 

Russell Ford, Fellow

Russell Ford, Fellow

Technical Advisor

Russell Ford has over 18 years experience in the design and development of innovative medical products and manufacturing processes. Russell’s expertise includes wearable and implantable devices, surgical equipment and complex drug delivery devices. Russell’s has a long history of senior level positions at Zosano Pharma, Abbott Medical Optics, Boston Scientific Neurovascular, and Cygnus Therapeutics. His expertise focuses on applications that include transdermal drug delivery, continuous glucose monitoring, minimally-invasive devices for cataract and laser surgery, as well as neuro-endovascular applications. Russell project management expertise ranges from early stage development through V&V, DFM, high volume scale-up, and commercial launch. Experience also includes development of system level, design, characterization, test method development, materials selection, supplier development, manufacturing process design, and quality systems. 

Chris Mitchell, PhD

Chris Mitchell, PhD

Technical Advisor

Dr. Chris Mitchell has more than 25 years of hands-on and leadership experience in the design, development, and characterization of innovative x ray-based imaging systems for medical and industrial applications. Before joining Triple Ring Technologies, Dr. Mitchell served in a variety of positions at Alara, Inc., including VP of R&D and Chief Scientific Officer. While there, he led the development of a patented, award-winning bone densitometer, and several computed radiography-based imaging systems for medical, industrial, and veterinary applications. Prior to Alara, Dr. Mitchell served as Manager, Imaging Technologies, at ARACOR, where he led the development of a number of innovative imaging systems, including high-performance digital radiography, and cone-beam computed tomography for high resolution bone imaging and reverse engineering applications. Chris received his B.A. in applied mathematics from Weber State University, and MS (bioengineering) and Ph.D. (electrical engineering) from the University of Utah. He holds 3 patents in the fields of bone densitometry and computed radiography and has authored or co-authored numerous presentations and journal articles. He is a member of the American Association of Physicists in Medicine (AAPM). 


Prisma Imaging
Sep 30, 2022
$10k - $1.07M
Common Stock
Preferred Stock

Maximum Number of Shares Offered subject to adjustment for bonus shares

*Maximum Number of Shares Offered subject to adjustment for bonus shares. See Bonus info below.


Friends and Family Early Birds

Invest within the first 48 hours and receive 20% bonus shares


Super Early Bird Bonus

Invest within the first week and receive 15% bonus shares


Early Bird Bonus

Invest within the first two weeks and receive 10% bonus shares



Receive 5% Bonus Shares

Receive 10% Bonus Shares 

Receive 15% Bonus Shares

Receive 20% Bonus Shares + Zoom call or in-person meeting with the founder

*All perks occur when the offering is completed.

The 10% StartEngine Owners' Bonus

Prisma Imaging will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.

This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $1.00 / share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $100. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.

This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.

Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus in addition to the aforementioned bonus.

Irregular Use of Proceeds

The Company will not incur any irregular use of proceeds.


Article Image
Prisma Partners With B.W. Furlong & Associates, Company To Receive Inaugural Imaging System

Prisma has come to mutually agreeable terms with B.W. Furlong & Associates to be the recipient of Prisma's first robotic imaging system. This agreement represents a significant milestone that validates the equine veterinary community's demand for Prisma's novel technology.

Article Image

Prisma Founder and CEO Michael Silver was a guest on The Horse Talk Show on September 23. He discussed how the Prisma system is a game-changer in horse health care solving the shortcomings in current equine imaging technology.

Article Image
Prisma Develops the First-Ever Functional Full-Body Equine Veterinary Imaging System for a Standing Conscious Horse

Prisma Imaging has successfully developed a new system for equine diagnostic imaging that addresses the shortcomings of current technology. Founded in 2016, Prisma developed a system that captures CT and radiographic images of the entire anatomy of a standing, conscious horse.

Article Image
Diagnostic Tool Offers Medical-Grade Imaging In Standing Equines

Prisma Imaging has successfully developed a new system for equine diagnostic imaging that addresses the shortcomings of current technology. Founded in 2016, Prisma developed a system that captures CT and radiographic images of the entire anatomy of a standing, weight-bearing and conscious horse.

Article Image
Prisma Develops the First-Ever Functional Full-Body Equine Veterinary Imaging System for a Standing Conscious Horse

The advanced imaging capabilities established through Prisma’s research and development is different from anything available in the marketplace. The resulting system represents a game-changer for the overall effect on equine diagnostics and horse health care.



Notice of Material Change in Offering

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the Prisma Imaging offering. Here's an excerpt describing the specifics of the change:

Issuer is extending campaign end date and updating page

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.


Whitney Cummings Signs on as Prisma Social Media Infulencer



A picture containing text, clipart

Description automatically generated



Dateline: [Los Angeles, CA, August 2022] — Better known as a celebrated performer and successful creator of almost every form of entertainment, a lesser-known fact about Ms. Cummings is her unbridled love of horses and commitment to their health, safety, and more humane existence.  This passion is being harnessed to spread the word about Prisma and its mission to help keep horses healthy and safe. 


When Whitney learned about Prisma, it was clear how closely her and Prisma’s interests were aligned and a primary factor in why she decided to help amplify their shared mission of promoting a better quality of life for our beloved four-legged friends.  


“Not enough is being done to protect these majestic, wonderful creatures”, commented Ms. Cummings.  They serve us in so many ways beyond entertainment and recreation that most people are not aware of. I’m excited about the platform that Prisma will offer me to help inform the public of the critical role that horses represent for us.” 

           Whitney with her rescue horse “King”


Prisma’s founder and CEO Michael Silver commented, “I know how rare it is for Whitney to endorse anything.  It’s why I so greatly appreciate and couldn’t be more enthusiastic about her helping us in telling Prisma’s story about how important horses are in so many ways.”



The New Standard of Care for Equine Diagnostics

Standing computed tomography of the equine limb: The new standard of care

The effectiveness of standing CT for horses was explored and substantiated in a paper written by Mahmoud Mageed in November 2020.  

In a recent survey conducted among equine veterinary professionals, there was a one hundred positive consensus that radiographic and CT imaging is the go-to modality to proactively detect latent defects or injuries and that a better means to image horses were needed. They also agreed that Prisma’s system would be a solution to the shortcomings in equine imaging. 

“CT imaging is the gold standard for the detection of latent defects and injuries. A system that can perform this on a conscious patient and image the axial skeleton will truly revolutionize equine imaging and diagnostics.”

Dr. Kurt Selberg, MS DVM MS DACVR

“In our practice, the more advanced imaging we can perform in a sedated standing horse allows us to use it much more.”

Dr. Brendan W. Furlong, MVB MRCVS

“The "black box" diagnostic dilemma in equine medicine is the axial skeleton. Any system that can provide useful information about the anatomy and pathology in the axial spine is likely to gain acceptance by practicing veterinarians.” 

Dr. Paul D. McClellan, DVM




Graphical user interface

Description automatically generated with low confidence


The Importance of Equine Therapy

Horses play an essential role, beyond entertainment and recreation, in the health and welfare of people.  In addition to protecting the $122 billion horse industry in the U.S., keeping horses healthy and safe is essential.  

What Is Equine Therapyfalse

Equine therapy is an experiential treatment method that uses the connection between people and horses to enhance physical or emotional healing. Different forms of equine therapy may be used depending on the client's needs.

Benefits of Equine Therapy

Typically, Equine Therapy is one component of a comprehensive treatment plan, meant to complement conventional approaches appropriate for the specific situation. Equine therapy sessions should always be led by a certified Equine-Assisted therapist, who has received specialized training in equine therapy, as well as traditional training in the mental health field.

The interaction between horse and client often unlocks blocked emotions, allowing them to be processed and healed. Equine therapist Nancy Jarrell states, “I continue to marvel at how a horse can behave in a certain way that results in the presentation of a crucial issue for a client. It is as though the horse already knows the history.”

Certain equine-assisted therapies are effective for children with cerebral palsy, behavioral tics, motor control issues, and coordination problems, and for people of any age with reduced mobility.

Research has found Equine Therapy to also be beneficial for those with eating disorders like anorexia and bulimia. The therapy helps individuals to better manage their emotions and learn to express feelings more positively. Riding and caring for the horses improve self-esteem and anxiety and improve negative body issues.

Most participants in Equine Therapy benefit from the unconditional acceptance offered by the horses they work with.

Keeping horses healthy and safe through better diagnostics is at the core of Prisma Imaging’s mission. Help support this important cause. 


Let us know what you think.



Part of Prisma’s mission is to build a community of horse lovers and those that want to see a safer, more humane existence for the animals that are part of everyone’s lives, including our beloved pets, animals in captivity, and those in our food chain. 


We’d love to hear your story about your connection to our four-legged friends and what inspires you to support this critical mission


Please share your story in the comments section below.   Three stories that best resonate with this cause will be selected, and the submitters will get a meeting with Prisma’s founder and CEO, Michael Silver.


We can’t wait to hear from you!


Our Community Joins In! | Insider Investment Notice

We're excited to see our community come in and invest in Prisma Imaging! 

Our Insiders have invested a total of $11,300 into the offering to date!
We hope you join in as well! Invest in Prisma Imaging

Please refer to the Company’s offering materials for further information and refer to the Company’s Risk Factors.




Prisma Founder and CEO Michael Silver was a guest on The Horse Talk Show. He discussed how the Prisma system is a game-changer in horse health care solving the shortcomings in current equine imaging technology.


The Horse Show Talk features all breeds, all disciplines, and lots of top equestrians. Live-stream horse broadcasts, with medical advice from some of the top veterinarians, interviews with the most well-known equestrians from all disciplines, ‘how-tos’ from equine experts, plus exciting interviews from events like the Kentucky Derby, Live Oak International, and more. For all things equine, listen to Louisa Barton and start living vicariously through a variety of thrilling horse adventures.

For more about the podcast visit


Prisma is the next generation of equine imaging focused on the development of new imaging techniques capable of capturing the never-before-seen perspectives of the equine patient.

The revolutionary Prisma system captures high-quality equine radiography and CT images of the entire anatomy of a standing, weight-bearing, conscious horse allowing for a safer and more effective, and efficient diagnosis, prognosis, and overall improved horse health care.

For more information, contact Prisma.


Prisma CEO Presents at 2022 Emerging Tech Showcase

Prisma was selected to be one of seventeen companies to present at the 2022 Emerging Tech Showcase, an event that features ventures that are developing new “cutting-edge technology.

Watch Video

“I was thrilled and honored to have Prisma be among this elite group of companies that represented some of the newest and most innovative technology that I have seen."

Michael Silver

Founder & CEO

Invest now and receive 10% Bonus Shares

Click Here

Owners bonus
Stack Owner's Bonus & Rewards!

Members get an extra 10% shares in addition to rewards below!


Multiple investments in an offering cannot be combined to qualify for a larger campaign perk. Get rewarded for investing more into Prisma Imaging.



Monika Fleischer

a year ago

I’m not an equestrian, however, I’m drawn to the beauty and energy that horses, and all animals exude. As a child I have many fond memories from being around horses and have always had pets. We share this planet with animals and we need to be more conscious of how they are treated. I feel that any technology that can help promote a safer, more humane existence is a great cause to support.




Cancel anytime before 48 hours before a rolling close or the offering end date.



We want you to succeed and get the most out of your money by offering rewards and memberships!


Your info is your info. We take pride in keeping it that way!


Invest in over 200 start-ups and collectibles!

With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.

With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.

At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.

Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.

StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.

For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.

For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.

Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.

Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.

Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.


@ 2022 All Rights Reserved

Apple Store Logo

Get To Know Us

Our Team



Important Message


Unless indicated otherwise with respect to a particular issuer, all securities-related activity is conducted by regulated affiliates of StartEngine: StartEngine Capital, LLC, a funding portal registered here with the US Securities and Exchange Commission (SEC) and here as a member of the Financial Industry Regulatory Authority (FINRA), or StartEngine Primary, LLC, a broker-dealer registered with the SEC and FINRA/SIPC . You can review the background of our broker-dealer and our investment professionals on FINRA’s BrokerCheck here. StartEngine Secondary is an alternative trading system regulated by the SEC and operated by StartEngine Primary, LLC, a broker dealer registered with the SEC and FINRA. StartEngine Primary, LLC is a member of SIPC and explanatory brochures are available upon request by contacting SIPC at (202) 371-8300.

Investment opportunities posted and accessible through the site are of three types:

1) Regulation A offerings (JOBS Act Title IV; known as Regulation A+), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Primary, LLC (unless otherwise indicated). 2) Regulation D offerings (Rule 506(c)), which are offered only to accredited investors. These offerings are made through StartEngine Primary, LLC. 3) Regulation Crowdfunding offerings (JOBS Act Title III), which are offered to non-accredited and accredited investors alike. These offerings are made through StartEngine Capital, LLC. Some of these offerings are open to the general public, however there are important differences and risks.

Any securities offered on this website have not been recommended or approved by any federal or state securities commission or regulatory authority. StartEngine and its affiliates do not provide any investment advice or recommendation and do not provide any legal or tax advice with respect to any securities. All securities listed on this site are being offered by, and all information included on this site is the responsibility of, the applicable issuer of such securities. StartEngine does not verify the adequacy, accuracy or completeness of any information. Neither StartEngine nor any of its officers, directors, agents and employees makes any warranty, express or implied, of any kind whatsoever related to the adequacy, accuracy, or completeness of any information on this site or the use of information on this site. See additional general disclosures here.

By accessing this site and any pages on this site, you agree to be bound by our Terms of use and Privacy Policy, as may be amended from time to time without notice or liability.

Canadian Investors Investment opportunities posted and accessible through the site will not be offered to Canadian resident investors. Potential investors are strongly advised to consult their legal, tax and financial advisors before investing. The securities offered on this site are not offered in jurisdictions where public solicitation for offerings is not permitted; it is solely your responsibility to comply with the laws and regulations of your country of residence.

California Investors Only – Do Not Sell My Personal Information (800-317-2200). StartEngine does not sell personal information. For all customer inquiries, please write to

StartEngine’s Reg A+ offering is made available through StartEngine Crowdfunding, Inc. This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For more information about this offering, please view StartEngine’s offering circular and risk associated with this offering.